Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities.

Acta biochimica et biophysica Sinica - 1 Jan 2016

Zhang Jun, Park Dongkyoo, Shin Dong M, Deng Xingming

Abstract excerpt

Oncogenic mutations in Kirsten rat sarcoma viral oncogene homolog (KRAS) occur in 15%-30% of non-small cell lung cancer (NSCLC). However, despite decades of intensive research, there is still no direct KRAS inhibitor with clinically proven efficacy. Considering its association with poor treatment response and prognosis of lung cancer, developing an effective inhibitory approach is urgently needed. Here, we review...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, ras

Share to Lung Neoplasms

Share to Prognosis

Share to Proto-Oncogene Proteins p21(ras)

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 26578706
DOI: 10.1093/abbs/gmv118
PMCID: PMC4689161

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities.PMID 26578706Read ↗

Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future.Semantic proximity Read ↗

Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications.Semantic proximity Read ↗

Targeting the KRAS Pathway in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

First-line treatments for KRAS-mutant non-small cell lung cancer: current state and future perspectives.Semantic proximity Read ↗

Targeting KRASG12D mutation in non-small cell lung cancer: molecular mechanisms and therapeutic potential.Semantic proximity Read ↗

Advances in targeting KRAS mutations: A promising approach for the treatment of non‑small cell lung cancer (Review).Semantic proximity Read ↗

On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma.Semantic proximity Read ↗

KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target.Semantic proximity Read ↗

KRAS mutant lung cancer: progress thus far on an elusive therapeutic targetSemantic proximity Read ↗

Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments.Semantic proximity Read ↗

[Current status and outlook of medical treatment for KRAS-mutated non-small cell lung cancer].Semantic proximity Read ↗

KRAS-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future Challenges.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.